Skip to content
Friday, November 8, 2024
Wall Street Insider
Deliver critical advise to busy investors
Search
Search
News
About Us
Services
Institutional Research
Portfolio Analysis
#1 Stock Pick
Subscriptions
Contact Us
CLIENT LOGIN
Home
News
AbbVie says FDA approves Skyrizi for ulcerative colitis
News
AbbVie says FDA approves Skyrizi for ulcerative colitis
June 19, 2024
Arthur Bleemer
AbbVie said that the heavily-advertised drug was now approved for four conditions across different so-called “immune-mediated” inflammatory diseases.
Read more from source
Post navigation
Trump Media shares continue to drop, as SEC move threatens to ding shareholders
Japan’s exports rise for sixth straight month, thanks to cars and chip equipment